1. Volume 11, Issue 6, Pages 735-739 (December 2012)
The Global Cell Therapy Industry Continues to Rise during the Second and Third Quarters of 2012 
Chris Mason, Mark J. McCall, Emily J. Culme-Seymour, Shalini Suthasan, Simon Edwards-Parton, Gregory A. Bonfiglio, Brock C. Reeve 
Cell Stem Cell 
Volume 11, Issue 6, Pages (December 2012)
DOI: /j.stem
Copyright © 2012 Elsevier Inc. Terms and Conditions

2. Figure 1
Share Price Movement for the First Three Quarters of 2012 Compared to the Close of Q4 2011
The share price for the end of 2011 was taken as the base point, and the percentage change from this for each quarter for individual companies has been plotted. The graph order of the companies was then established in terms of their overall change to the end of Q3 2012, with those that had the biggest Q to Q positive change on the left. Splits and reverse splits have been factored in. See also Table S1 for the underlying stock price information used to generate this graph.
Cell Stem Cell  , DOI: ( /j.stem )
Copyright © 2012 Elsevier Inc. Terms and Conditions

3. Figure 2
Clinical Trial Data for Ongoing Clinical Trials being Conducted by Publicly Listed Cell Therapy Companies at the Close of Q3 2012
Data was solely sourced from and only includes the “ongoing” cell therapy trials for the individual companies (i.e., they do not include their other non-cell-based activities) and for where the company acted as a “sponsor” and/or “collaborator.” Multinational pharma, biotech, and medical device companies are excluded. See Table S2 for the underlying data used to generate this graph.
Cell Stem Cell  , DOI: ( /j.stem )
Copyright © 2012 Elsevier Inc. Terms and Conditions